MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598267 | Name: Deslanosid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deslanosid is a cardiotonic glycoside from the leaves of Digitalis lanata.

Chemical Structure

Deslanosid
Deslanosid
CAS#17598-65-1

Theoretical Analysis

MedKoo Cat#: 598267

Name: Deslanosid

CAS#: 17598-65-1

Chemical Formula: C47H74O19

Exact Mass: 942.4824

Molecular Weight: 943.09

Elemental Analysis: C, 59.86; H, 7.91; O, 32.23

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Deslanosid; Ceglunat; Lanatosid C; Sediranido; Desacetyllanatoside C; Deacetyllanatoside C; Cedilanid-D; Desace; Deslanosido; Deslanosidum; Lekozid;
IUPAC/Chemical Name
4-((3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-(((2R,4S,5S,6R)-4-hydroxy-5-(((2S,4S,5S,6R)-4-hydroxy-5-(((2S,4S,5S,6R)-4-hydroxy-6-methyl-5-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one
InChi Key
OBATZBGFDSVCJD-LALPQLPRSA-N
InChi Code
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
SMILES Code
O=C1OCC([C@H]2CC[C@]3(O)[C@]4([H])CC[C@]5([H])C[C@@H](O[C@H]6C[C@@H]([C@@H]([C@@H](C)O6)O[C@H]7C[C@@H]([C@@H]([C@@H](C)O7)O[C@H]8C[C@@H]([C@@H]([C@@H](C)O8)O[C@H]9[C@@H]([C@H]([C@@H]([C@@H](CO)O9)O)O)O)O)O)O)CC[C@]5(C)[C@@]4([H])C[C@@H](O)[C@]23C)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 943.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chen DP, Xiong YJ, Tang ZY, Yao QY, Ye DM, Liu SS, Lin Y. Characteristics of deslanoside-induced modulation on jejunal contractility. World J Gastroenterol. 2012 Nov 7;18(41):5889-96. doi: 10.3748/wjg.v18.i41.5889. PubMed PMID: 23139604; PubMed Central PMCID: PMC3491595. 2: Gillis RA, Jolson H, Thibodeaux H, Levitt B. Antagonism of deslanoside-induced cardiotoxicity by combined nicotinic and muscarinic blockade of autonomic ganglia. J Pharmacol Exp Ther. 1975 Oct;195(1):126-32. PubMed PMID: 241837. 3: Bakke OM, Aslaksen A, Lehmann V, Lien E. Pharmacokinetics and serum concentration--effect relationship of intravenous deslanoside. J Cardiovasc Pharmacol. 1981 Sep-Oct;3(5):1015-25. PubMed PMID: 6168847. 4: Helke CJ, Kellar KJ, Gillis RA. Effect of in vivo deslanoside on the uptake of serotonin into platelets. Arch Int Pharmacodyn Ther. 1979 Nov;242(1):44-9. PubMed PMID: 543748. 5: Klys M, Gross A. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8. PubMed PMID: 2193860. 6: Tada A, Kitazawa M, Horasawa K, Zenda H, Kawa S, Oguchi T, Honma T, Furuta S. [Pharmacokinetics of deslanoside in man]. Yakugaku Zasshi. 1982 Nov;102(11):1061-6. Japanese. PubMed PMID: 7182446. 7: Kobayashi M, Shimotori M, Chiba S. Direct effects of digoxin and deslanoside on sinoatrial conduction in isolated, blood-perfused dog atria. Jpn Heart J. 1983 Jul;24(4):649-55. PubMed PMID: 6645055. 8: Ambrosioni E, Costa FV, Bracchetti D. Comparison of hemodynamic effects induced by pentaformilgitoxin and deslanoside in patients with heart failure. Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):416-20. PubMed PMID: 500257. 9: Marzo A, Ghirardi P, Maggi GC, Tornaghi A, Di Roberto F, Arisi GP. Plasma turnover and biliary and urinary excretion of deslanoside C-3H in man. Farmaco Prat. 1980 May;35(5):265-9. PubMed PMID: 7449946. 10: Helke CJ, Souza JD, Gillis RA. Interaction of serotonin and deslanoside on cardiac rhythm in the cat. Eur J Pharmacol. 1978 Sep 15;51(2):167-77. PubMed PMID: 699982. 11: Marzo A, Ghirardi P, Cavalca L, Alessio R, Maggi GC, Piscitello F, Triulzi MO. Plasma turnover and excretion of deslanoside C-3H in man after parenteral administration. Farmaco Prat. 1981 Nov;36(11):501-12. PubMed PMID: 7308424. 12: Fujii Y, Ikeda Y, Yamazaki M. Determination of cardiac glycosides in digitoxin tablets and deslanoside injections by micro-HPLC. J Chromatogr Sci. 1990 Jun;28(6):288-91. PubMed PMID: 2246351. 13: Tokunaga H, Kimura T, Kawamura J. [The National Institute of Hygieneic Sciences Reference Standard (The Japanese Pharmacopoeia Standard) "Deslanoside Reference Standard" (author's transl)]. Eisei Shikenjo Hokoku. 1979;(97):113-4. Japanese. PubMed PMID: 543941. 14: Helke CJ, Yuhaniak PA, Kellar KJ, Gillis RA. Effect of deslanoside on brain and spinal cord levels of serotonin and 5-hydroxy-indoleacetic acid and tryptophan hydroxylase activity. Biochem Pharmacol. 1978;27(20):2459-61. PubMed PMID: 728197. 15: SHARE NN, CHAI CY, WANG SC. EMESIS INDUCED BY INTRACEREBROVENTRICULAR INJECTIONS OF APOMORPHINE AND DESLANOSIDE IN NORMAL AND CHEMORECEPTIVE TRIGGER ZONE ABLATED DOGS. J Pharmacol Exp Ther. 1965 Mar;147:416-21. PubMed PMID: 14269619. 16: Marzo A, Ghirardi P, Barlattani M, Lentini S. Pharmacokinetics of deslanoside C-3H administered orally to healthy volunteers. Farmaco Prat. 1982 Jan;37(1):28-37. PubMed PMID: 7056373. 17: Juhlin L, Shelley WB. Deslanoside and ouabain inhibition of endotoxin-induced microclots. Acta Pharmacol Toxicol (Copenh). 1981 Sep;49(3):236-8. PubMed PMID: 7336981. 18: ESKWITH IS, FOGARTY TF. The treatment of auricular arrhythmias with deslanoside. Am J Cardiol. 1958 Nov;2(5):579-85. PubMed PMID: 13594846. 19: Helke CJ, Souza JD, Hamilton B, Gillis R. No evidence for a central serotonergic mechanism in arrhythomogenic effects of deslanoside. Nature. 1978 Aug 31;274(5674):925. PubMed PMID: 683337. 20: Dubiel JP, Kolasińska-Kloch W. [Effect of deslanoside on the right-ventricular function of the healthy heart]. Pol Arch Med Wewn. 1980 Oct;64(4):299-308. Polish. PubMed PMID: 7454594.

View History

Monoethanolamine-iodine

Monoethanolamine-iodine